Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
Fiction
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/1c/28/46/1c284650-49d4-6634-9910-779ba4c2e726/mza_1942905218397286773.jpg/600x600bb.jpg
Future Science Group
Taylor & Francis Group
302 episodes
1 week ago
Exploring biomarker testing in bioanalytical Contract Research Organizations
Show more...
Science
RSS
All content for Future Science Group is the property of Taylor & Francis Group and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Exploring biomarker testing in bioanalytical Contract Research Organizations
Show more...
Science
https://i1.sndcdn.com/artworks-twze99wf7ynN4Cv6-T6KaiA-t3000x3000.png
Cell therapies for autoimmune diseases: a podcast with Lindsay Davies
Future Science Group
13 minutes 17 seconds
8 months ago
Cell therapies for autoimmune diseases: a podcast with Lindsay Davies
This International Women’s Day, we’re joined by Lindsay Davies, Chief Scientific Officer at NextCell Pharma (Stockholm, Sweden), to discuss the evolving role of cell therapies in treating autoimmune diseases. In this podcast, Davies breaks down the science behind NextCell’s mesenchymal stromal cell therapy for type 1 diabetes and explores how these cells could be applied to other autoimmune conditions. She emphasizes the importance of tailoring cell therapies based on disease type, stage and patient profile to achieve the best outcomes. The conversation also highlights how growing evidence of sex-related differences will could increasingly shape decisions in the development and testing of cell therapies.
Future Science Group
Exploring biomarker testing in bioanalytical Contract Research Organizations